Changes in PKM2 Associate with Prostate Cancer Progression

REFERENCES

• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519–530.
   PubMedGoogle Scholar
• Warburg O. On the origin of cancer cells. Science 1956;123:309–314.
   PubMed Web of Science ®Google Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703–707.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–1033.
   PubMed Web of Science ®Google Scholar
• Wong N, De Melo J, Tang D. PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol 2013;2013:242–513.
   Google Scholar
• Yamada K, Noguchi T. Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem J 1999;337:1–11.
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature 2008;452:230–233.
   PubMed Web of Science ®Google Scholar
• Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G. Land. M2 pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Archiv 1994;424:177–185.
   PubMed Web of Science ®Google Scholar
• Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2 pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002;22:311–318.
   PubMed Web of Science ®Google Scholar
• Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2 PK). Anticancer Res 1999;19:2583–2590.
   PubMed Web of Science ®Google Scholar
• Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH. The pyruvate kinase isoenzyme tumor M2 (Tu M2 PK) as a tumor marker for renal carcinoma. Anticancer Res 1999;19:2599–2601.
   PubMed Web of Science ®Google Scholar
• Pottek T, Müller M, Blum T, Hartmann M. Tu M2 PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000;20:5029-5033.
   PubMed Web of Science ®Google Scholar
• Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2 PK) in human carcinomas. Anticancer Res 1997;17:3153–3156.
   PubMed Web of Science ®Google Scholar
• Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000;20:5077–5082.
   Google Scholar
• Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol 2001;22:282–285.
   PubMed Web of Science ®Google Scholar
• Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005;15:300–308.
   PubMed Web of Science ®Google Scholar
• Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011;2:393–400.
   PubMed Web of Science ®Google Scholar
• Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH, Cho JY. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 2012;18:4037–4043.
   PubMed Web of Science ®Google Scholar
• Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, Edenfield H, Mani M, Colquitt R, Maulik G, Van Oss B, Sugarbaker DJ, Bueno R. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 2009;101:678–686.
   PubMed Web of Science ®Google Scholar
• Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Ondo H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H. Mammalian target of rapamycin upregulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011;108:4129–4134.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang J, Manley JL. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res 2012;70:8977–8980.
   Web of Science ®Google Scholar
• Garcia Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, Anastasiou D, Ito K, Sasaki AT, Rameh L, Carracedo A, Vander Heiden MG, Cantley LC, Pinton P, Haigis MC, Pandolfi PP. Systemic elevation of PTEN induces a tumor suppressive metabolic state. Cell 2012;149:49–62.
   PubMed Web of Science ®Google Scholar
• Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR, and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans 2013;41:917–922.
   PubMed Web of Science ®Google Scholar
• Kavanagh JP. Isocitric and citric acid in human prostatic and seminal fluid: implications for prostatic metabolism and secretion. Prostate 1994;24:139–142.
   PubMed Web of Science ®Google Scholar
• Medrano A, Fernandez-Novell JM, Ramio L, Alvarez J, Goldberg E, Montserrat River M, Guinovart JJ, Rigau T, Rodriguez-Gil JE. Utilization of citrate and lactate through a lactate dehydrogenase and ATP-regulated pathway in boar spermatozoa. Mol Reprod Dev 2006;73:369–378.
   PubMed Web of Science ®Google Scholar
• Mycielska ME, Patel A, Rizaner N, Mazurek MP, Keun H, Patel A, Ganapathy V, Djamgoz MB. Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer. Bioessays 2009;31:10–20.
   PubMed Web of Science ®Google Scholar
• Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med 2013;54:1685–1688.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol 2009;472:439–453.
   Google Scholar
• Ross JS. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test. Adv Anat Pathol 2007;14:353–357.
   PubMed Web of Science ®Google Scholar
• Moon C, Park JC, Chae YK, Yun JH, Kim S. Current status of experimental therapeutics for prostate cancer. Cancer Lett 2008;266:116–134.
   PubMed Web of Science ®Google Scholar
• Rybak AP, He L, Kapoor A, Cutz JC, Tang D. Characterization of sphere­-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta 2011;1813;683–694.
   PubMed Web of Science ®Google Scholar
• O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007–4021.
   PubMed Web of Science ®Google Scholar
• Gorg A, Drews O, Luck C, Weiland F, Weiss W. 2 DE with IPGs. Electrophoresis 2009;30:S122–S132.
   PubMed Web of Science ®Google Scholar
• Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C. Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone naive prostate cancer and are elevated in castration resistant disease. Endocr Relat Cancer 2013;20:403–413.
   PubMed Web of Science ®Google Scholar
• Patrawala L, Calhoun T, Schneider Broussard R, Li H, Bhatia S, Tang JG, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696–1708.
   PubMed Web of Science ®Google Scholar
• Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, Lei QY. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone mediated autophagy and promotes tumor growth. Mol Cell 2011;42:719–730.
   PubMed Web of Science ®Google Scholar
• Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011;334:1278–1283.
   PubMed Web of Science ®Google Scholar
• Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res 2012;18:5554–5561.
   PubMed Web of Science ®Google Scholar
• Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, Sugihara E, Onishi N, Yamamoto T, Yanagawa H, Suematsu M, Saya H. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012;72:1438–1448.
   PubMed Web of Science ®Google Scholar
• Cortés­Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR, Hofmann F. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA 2013;110:489–494.
   PubMed Web of Science ®Google Scholar
• Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, Granfors T, Fowler CJ. Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One 2012;7: e47994.
   PubMed Web of Science ®Google Scholar
• Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011;2:393–400.
   PubMed Web of Science ®Google Scholar
• Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2014;S0304-3835(14):00088–3.
   Google Scholar
• Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012;198:281–293.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755–768.
   PubMed Web of Science ®Google Scholar
• Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS, Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 2011;108:16062–16067.
   PubMed Web of Science ®Google Scholar
• Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun­Davis T, Li H, Palapattu GS, Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG. The PSA (/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012;10:556–569.
   PubMed Web of Science ®Google Scholar
• Moul JW, Dawson N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Invest 2012;30:1–12.
   PubMed Web of Science ®Google Scholar
• Hitosugi T, Kang S, Vander Heiden MG, Chung T, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009;97:ra73.
   Google Scholar
• Yu Z, Zhao X, Huang L, Zhang T, Yang F, Xie L, Song S, Miao P, Zhao L, Sun X, Liu J, Huang G. Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase (PKM2) and promotes glycolysis in cancer cells. J Biol Chem 2013;288:35406–35416.
   PubMed Web of Science ®Google Scholar
• Lv L, Xu Y, Zhao D, Li F, Wang W, Sasaki N, Jiang Y, Zhou X, Li T, Guan K, Lei Q, Xiong Y. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell 2013;52:340–352.
   PubMed Web of Science ®Google Scholar
• Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 2012;14:1295–1304.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11–22.
   PubMed Web of Science ®Google Scholar
• LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002;62:4499–4506.
   PubMed Web of Science ®Google Scholar
• Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790–2799.
   PubMed Web of Science ®Google Scholar
• Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68:927–936.
   PubMed Web of Science ®Google Scholar
• Gao X, Wang H, JYang JJ, Liu XZR. Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 2012;45:598–609.
   PubMed Web of Science ®Google Scholar
• Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 2011;480:118–122.
   PubMed Web of Science ®Google Scholar
• Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Yung WK, Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012;150:685–96.
   PubMed Web of Science ®Google Scholar